Literature DB >> 11410507

Loss of H-cadherin protein expression in human non-small cell lung cancer is associated with tumorigenicity.

Y Zhong1, Y Delgado, J Gomez, S W Lee, R Perez-Soler.   

Abstract

Abnormalities in the H-cadherin gene have been described in several human cancers. However, their biological significance remains undetermined. To investigate the role of H-cadherin in non-small cell lung cancer (NSCLC), a chimera H-cadherin-green fluorescent protein (GFP) expressed in Cos-7 cells was used to identify an anti-H- cadherin antibody, HCD-1. Western blot analysis was performed in six NSCLC cell lines and 35 pairs of primary NSCLC tumors and nonmalignant lung tissue obtained from surgical resections using HCD-1. Loss of H-cadherin expression was seen in five (83%) of the six NSCLC cell lines, whereas loss of E-cadherin was seen in three (50%) of the six. H-cadherin expression was lost in 15 (43%) of 35 NSCLC surgical tumor specimens, whereas E-cadherin expression was lost in 6 (17%) of 35. H-cadherin was expressed in all of the nonmalignant lung tissue from all of the surgical specimens. Fourteen of 35 tumors were heterotransplanted s.c. in nude mice. Tumorigenicity in nude mice was associated with both loss of H-cadherin expression (P = 0.03) and loss of E-cadherin expression (P = 0.05). Loss of H-cadherin was also associated with a more advanced local tumor growth, although the difference was not significant. The results indicate that loss of H-cadherin is frequent in human NSCLC and suggest that it facilitates the implantation and local growth of human NSCLC tumors.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11410507

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  9 in total

1.  T-cadherin-mediated cell growth regulation involves G2 phase arrest and requires p21(CIP1/WAF1) expression.

Authors:  Zhi-yong Huang; YanLi Wu; Nicolé Hedrick; David H Gutmann
Journal:  Mol Cell Biol       Date:  2003-01       Impact factor: 4.272

2.  DNA methylation changes in atypical adenomatous hyperplasia, adenocarcinoma in situ, and lung adenocarcinoma.

Authors:  Suhaida A Selamat; Janice S Galler; Amit D Joshi; M Nicky Fyfe; Mihaela Campan; Kimberly D Siegmund; Keith M Kerr; Ite A Laird-Offringa
Journal:  PLoS One       Date:  2011-06-23       Impact factor: 3.240

3.  Prognostic significance of CDH13 hypermethylation and mRNA in NSCLC.

Authors:  Ruilin Xue; Cuili Yang; Fang Zhao; Dejia Li
Journal:  Onco Targets Ther       Date:  2014-10-31       Impact factor: 4.147

4.  Clinicopathological significance and potential drug target of T-cadherin in NSCLC.

Authors:  Zhidong Wang; Bin Wang; Huanchen Guo; Guoyu Shi; Xiuqin Hong
Journal:  Drug Des Devel Ther       Date:  2014-12-19       Impact factor: 4.162

5.  Aerosol azacytidine inhibits orthotopic lung cancers in mice through Its DNA demethylation and gene reactivation effects.

Authors:  Xuan Qiu; Yuanxin Liang; Rani S Sellers; Roman Perez-Soler; Yiyu Zou
Journal:  PLoS One       Date:  2014-10-27       Impact factor: 3.240

6.  Implications of the Adiponectin System in Non-Small Cell Lung Cancer Patients: A Case-Control Study.

Authors:  Ersilia Nigro; Fabio Perrotta; Maria Ludovica Monaco; Rita Polito; Pia Clara Pafundi; Maria Gabriella Matera; Aurora Daniele; Andrea Bianco
Journal:  Biomolecules       Date:  2020-06-18

7.  Cadherin 13 Inhibits Pancreatic Cancer Progression and Epithelial-mesenchymal Transition by Wnt/β-Catenin Signaling.

Authors:  Dengfei Xu; Hui Yuan; Zihong Meng; Chunmei Yang; Zefang Li; Mengge Li; Zhigang Zhang; Yu Gan; Hong Tu
Journal:  J Cancer       Date:  2020-02-03       Impact factor: 4.207

8.  Effects of T-cadherin expression on B16F10 melanoma cells.

Authors:  Xin-Suo Duan; Jie Lu; Zhi-Hua Ge; En-Hong Xing; Hai-Tao Lu; Li-Xin Sun
Journal:  Oncol Lett       Date:  2013-01-30       Impact factor: 2.967

9.  Genetic variation in CDH13 gene was associated with non-small cell lung cancer (NSCLC): A population-based case-control study.

Authors:  Yingfu Li; Chuanyin Li; Qianli Ma; Yu Zhang; Yueting Yao; Shuyuan Liu; Xinwen Zhang; Chao Hong; Fang Tan; Li Shi; Yufeng Yao
Journal:  Oncotarget       Date:  2017-12-05
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.